Australian Government invests in new medicines for COVID-19
2 June 2020 The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19. The funding from the Medical Research Future Fund (MRFF) will support…
Atmo Biosciences raises $2.5m in seed financing
2 June 2020 Melbourne and Sydney, Australia – Atmo Biosciences, a digital health business which provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an…
Dimerix Drug in WHO COVID-19 Trial
4 June 2020 Global platform trial taps Australian drug for major global COVID-19 treatment study As the world mobilises to bring to bear the full scientific resources it can to fight the COVID-19 pandemic, an Australian biotech…
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
1 June 2020 AbbVie, a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 is…
Certara Broadens and Increases Regulatory Strength with Two Executive Hires
21 May 2020 Certara®, the global leader in model-informed drug development and regulatory science announced the appointments of Terrance (Terry) Ocheltree, Ph.D., R.Ph. as vice president of regulatory strategy and chemistry, manufacturing and controls (CMC) and Lynne Georgopoulos,…
Human insulin enhanced with cone snail ‘blue print’
2 June 2020 Diabetes treatments could be improved following the development of a dramatically modified form of human insulin, called ‘Mini-Ins’, that successfully mimics the ultra-fast-acting properties of cone snail venom insulin. Mini-Ins has demonstrated significant promise…
Noxopharm: ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
1 June 2020 Highlights: NOX66 (Veyonda®) clinical data released to world-wide audience Anti-cancer responses (tumor size and pain responses) observed in approximately two-thirds of men with end-stage prostate cancer Abscopal responses in approximately one-quarter of men with end-stage…
Immutep Reports First Results from INSIGHT-004 Study
1 June 2020 First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCO Encouraging early activity signals in a variety of cancer indications Overall, 33% of patients showed…
Immutep Announces Improving Data from Phase II TACTI-002 Study
1 June 2020 First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC) Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR) Progression free survival (PFS) continues to improve in…
Immutep Receives A$3.6 Million R&D Tax Incentive from French Government
29 May 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~ A$3,630,000) research and development (R&D) tax incentive payment in cash…
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
26 May 2020 Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion…
Australia’s top scientists elected as Fellows of the Academy
25 May 2020 An Australian scientist who identified the cause of mass frog extinctions across the globe is among a group of scientists being acknowledged today for their outstanding contributions to science. Associate Professor Lee Berger’s research into…
